Copy of the communication sent to equity shareholders intimating the fixation of record date is submitted.

October 27, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code – 526783 Dear Sir / Madam, Sub: Disclosure under Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Letter to equity shareholders Further to our prior correspondence dated October 20, 2026, we wish to inform you that Dr. Agarwal’s Eye Hospital Limited (the “Company”) has sent email communications and dispatched physical letters to the equity shareholders whose email addresses are not registered or available with the Company, the Registrar and Transfer Agents, the Depository Participants, or the Depositories. This letter provides advance notice to the shareholders intimating the record date, i.e., Wednesday, November 18, 2026, which has been fixed for the purpose of the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited (“Transferor Company”) and Dr. Agarwal’s Health Care Limited (“Transferee Company”) and their respective shareholders and creditors. Copy of the aforesaid letter is enclosed herewith. We request you to kindly take the above on record. For Dr. Agarwal’s Eye Hospital Limited Meenakshi Jayaraman Company Secretary and Compliance Officer Encl.: as above. Dr. Agarwal’s Eye Hospital Limited CIN: L85110TN1994PLC027366 Regd. Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018 Tel: +91 44 4378 7777; Website: www.dragarwal.com; Email: investor@dragarwal.com ENVL_NO Date: October 27, 2026 NAME_1 CITY Dear Shareholder, Subject: Advance Intimation – Fixation of Record Date for Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited (“Transferor Company”) and Dr. Agarwal’s Health Care Limited (“Transferee Company”) and their respective shareholders & creditors We are pleased to inform you that the Hon'ble National Company Law Tribunal (NCLT), Chennai Bench, vide its order dated September 30, 2026, has sanctioned the Scheme of Amalgamation under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, amongst Dr. Agarwal’s Eye Hospital Limited (“Transferor Company” or “AEHL”) and Dr. Agarwal’s Health Care Limited (“Transferee Company” or “AHCL”) and their respective shareholders and creditors (“Scheme”). 1. Fixation of Record Date Notice is hereby given that the Board of Directors of the Company, in consultation with the Board of the Transferee Company, has fixed Wednesday, November 18, 2026, as the Record Date for determining the eligible equity shareholders of the Transferor Company who shall be entitled to receive fully paid-up equity shares of the Transferee Company pursuant to the Scheme. 2. Share Exchange Ratio Pursuant to Clause 18.1 of the Scheme, the share exchange ratio is: Eligible shareholders of Dr. Agarwal’s Eye Hospital Limited will receive 23 Equity Shares of face value ₹1/- each fully paid-up in Dr. Agarwal’s Health Care Limited for every 2 Equity Shares of face value ₹10/- each fully paid-up held in the Dr. Agarwal’s Eye Hospital Limited as on the Record Date (i.e., November 18, 2026). 3. Treatment of Fractional Entitlements No fractional equity shares will be issued directly to any shareholder. Fractional entitlements arising out of allotment of Equity Shares (if any) will be consolidated and allotted to the Trustee nominated by the Board, who shall hold these Shares in trust on behalf of the eligible Shareholders of the Company (Trustee 1). The Trustee 1 will sell these consolidated shares on the Stock Exchanges at market price within 90 (ninety) days from the date of allotment and distribute the net proceeds (after deducting applicable costs, expenses, and withholding taxes) to eligible shareholders in proportion to their respective fractional entitlements. 4.Mode of Allotment and Action Required by Shareholders For shares held in demat mode Pursuant to the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR) and the SEBI Master Circular on Schemes of Arrangement, the new equity shares of Dr. Agarwal’s Health Care Limited will be allotted in dematerialised form and credited directly to your respective beneficiary demat account maintained with your Depository Participant (DP) after obtaining the necessary regulatory and stock exchange approvals. Please ensure your demat account credentials (DP ID / Client ID) are active and up to date with your DP. For shares held in physical mode Equity shares allotted to shareholders holding physical share certificates as of the Record Date will be credited in dematerialized form to a dedicated Trustee Demat Account. These shares will be held in trust and released to beneficiaries upon submission and verification of the requisite demat details and documents. Action Recommended: Shareholders holding equity shares in physical form are strongly requested to take immediate steps to dematerialize their physical share certificates prior to November 18, 2026. 5.Registrar and Transfer Agent (RTA) Contact Details For any assistance or queries regarding your shareholding or dematerialization process, please contact the Registrar and Transfer Agent (“RTA”): Integrated Registry Management Services Private Limited Unit: Dr. Agarwal’s Eye Hospital Limited 2nd Floor, Kences Towers, No.1 Ramakrishna Street, North Usman Road, T Nagar, Chennai – 600 017. Contact No. (044) 2814 0801 / 803 Email: einward@integratedindia.in A separate communication / advice would be sent to the eligible shareholders post allotment and credit of the consideration shares. We thank you for your support and faith in the Company and for being an esteemed shareholder. Thanking You, Yours sincerely, For Dr. Agarwal’s Eye Hospital Limited Sd/- Meenakshi Jayaraman Company Secretary & Compliance Officer